Seeking Alpha

More on Edwards Lifesciences (EW): Q3 beats on a per share basis but comes up short on revenue...

More on Edwards Lifesciences (EW): Q3 beats on a per share basis but comes up short on revenue as sales growth in its transcatheter heart valves ran below expectations. Looking forward, the company says it expects a strong close to the year with today's FDA approval of expanded indications for SAPIEN, which will allow it to serve many more patients.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)